Amylyx Pharmaceuticals Inc. has announced the initiation of the LUMINA clinical trial, a Phase 1, multinational, randomized, double-blind, placebo-controlled study aimed at evaluating the safety and biological activity of its investigational drug, AMX0114, in individuals with amyotrophic lateral sclerosis (ALS). The trial will involve approximately 48 participants who will be randomized in a 3:1 ratio to receive either AMX0114 or placebo through intrathecal administration every four weeks, for a total of up to four doses. The study will also assess changes in ALS biomarkers, such as neurofilament light (NfL) levels. In conjunction with the trial, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AMX0114, which targets calpain-2, a contributor to axonal degeneration in ALS. Early data from the trial's cohorts are anticipated in 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。